What Okeiro does

Okeiro (legally Predict4Health SAS) is a Paris-based precision medicine company developing an AI-driven platform for transplantation and chronic disease management. Its core technology is the iBox algorithm, a multimodal predictive model that estimates individual risk of kidney allograft loss up to 10 years post-evaluation by integrating time from transplant, eGFR, proteinuria/creatininuria ratio, donor-specific antibodies, and biopsy findings. The iBox algorithm holds a C-statistic of 0.81 and has been validated across 7,557 patients in 10 academic centers in Europe and the US, plus a broader network of 44 transplant centers across 5 continents. The platform layers remote patient monitoring, intelligent alerts, predictive scoring, and e-prescribing on top of iBox, and extends into life sciences through sub-products TrialBox (iBox as a qualified surrogate endpoint for clinical trials), Digital Twin (synthetic control arms), and a Real World Evidence System that embeds study protocols into routine clinical workflows.

The company serves three stakeholder groups: healthcare professionals in hospital transplant centers managing kidney, cardiac, liver, and pulmonary insufficiency patients; transplant and chronic disease patients seeking proactive health management; and life sciences companies running clinical trials in transplantation. Its commercial model is enterprise SaaS — annual subscriptions sold through direct field sales to hospitals and pharmaceutical sponsors — with quote-based pricing and a nurse-integration support model for deployment. The company currently counts 500+ healthcare professionals using the platform and has deployed at leading French transplant centers, with stated intent to expand internationally.

Okeiro raised €10M in Series A funding in April 2025 (led by Alven, Forepont Capital Partners, and Red River West) and concurrently rebranded from Predict4Health to Okeiro to signal a broader strategic footprint beyond its founding scope. The funding is earmarked for international expansion and platform development. The company is GDPR-compliant, hosts on Google Cloud, and operates from a single Paris headquarters with approximately 30 dedicated team members.

Name

Okeiro

Legal name

Predict4Health

Website

https://okeiro.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Okeiro (Predict4Health SAS) is a Paris-based precision medicine company that sells an AI-driven platform for transplant and chronic disease care, anchored by the EMA/FDA-qualified iBox predictive algorithm and used by 500+ healthcare professionals across leading transplant centers in France and globally.

Ownership category

akta.pro rank

Product category

Precision Medicine Software

NAICS

Home Health Care Services (62161)

SIC

Services-Health Services (8000)

akta.pro primary industry

SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)

akta.pro secondary industries

AI/Analytics for RPM (Risk Stratification, Alerts, Predictive) (HLACAFAM), eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)

Keywords

• Precision medicine platform
• Transplant predictive analytics
• Remote patient monitoring
• Clinical trial surrogate endpoints
• Real-world evidence system

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Platform Licensing/Subscription: SaaS-based platform subscription model providing access to predictive algorithms, patient monitoring, and clinical trial support tools for healthcare institutions and life sciences companies.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Okeiro offers an AI-driven precision medicine platform for transplantation and chronic disease management, built around its validated iBox algorithm. The platform delivers remote patient monitoring with intelligent alerts and predictive graft-loss scoring, while specialized capabilities support clinical trials via synthetic control arms (Digital Twin) and large-scale real-world evidence generation for transplant and chronic disease cohorts.

Product overview

Okeiro offers a unified precision medicine platform for transplantation and chronic diseases, built around its validated iBox predictive algorithm. The core platform delivers remote patient monitoring with intelligent alerts and predictive scoring, while specialized modules include TrialBox for clinical trial acceleration using iBox as a surrogate endpoint, a Digital Twin for synthetic control arms, and a Real World Evidence System for conducting studies at scale. The platform is designed for three user segments: healthcare professionals requiring patient monitoring tools, patients seeking proactive health management, and life sciences companies conducting clinical research.

Differentiator

Problem solved

Functional benefit

Products and services

• iBox Algorithm A validated multimodal predictive algorithm that estimates individual risk of kidney allograft loss up to 10 years post-evaluation by integrating eGFR, proteinuria/creatininuria ratio, donor-specific antibodies, and biopsy findings. The first surrogate endpoint for kidney transplant clinical trials with EMA qualification and the first to reach stage 2 of FDA qualification, with a C-statistic of 0.81.
• Okeiro Platform A precision medicine platform bridging clinical care and research with validated predictive algorithms, delivering personalized interventions for transplant patients and those with kidney, cardiac, liver, and pulmonary insufficiencies, while accelerating therapeutic innovation through real-world evidence generation.
• TrialBox Clinical trial support system implementing the iBox algorithm as a surrogate endpoint to provide reliable predictions of long-term graft survival, help design more efficient studies, and assess drug efficacy and safety in real-world settings.
• Digital Twin Technology for creating synthetic control arms for clinical trials by generating matched control cohorts that mirror intervention group characteristics, reducing the need for prospective control groups and enabling trials in rare conditions.
• Real World Evidence System Platform capability for conducting real-world studies at scale by embedding study protocols into existing clinical care pathways, aggregating clinical documentation, biological, immunological, histological and genetic values, imaging results, medication administration data, and patient-reported outcomes.
• Remote Patient Monitoring Precision remote monitoring service for transplant patients and those with chronic diseases, featuring automatic data centralization, intelligent alerts for early warning signs, predictive graft loss scoring, and nurse integration to support healthcare providers.

Quantifiable outcome

• iBox C-statistic: 0.81 (0.79-0.83) for predicting long-term graft outcomes
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Owkin: French AI-for-healthcare company combining multimodal patient data with proprietary models to support clinical research and drug development. Highly comparable on origin (France), AI-driven multimodal approach, and pharma/biopharma customer base.
• Verana Health: Real-world evidence company that curates specialty disease databases (ophthalmology, neurology, urology) for clinical research and pharma decision-making. Closely aligned in building disease-specific evidence networks that pharma sponsors use to accelerate trials.
• Caresyntax: AI-driven surgical and clinical analytics platform aggregating intraoperative and outcomes data to support hospital performance and clinical research. Comparable as a multimodal clinical AI platform selling into hospitals and life sciences.
• Voluntis: French digital therapeutics company building SaMD platforms for chronic disease management and patient monitoring. Comparable as a French-origin digital health platform pairing patient monitoring with clinical research-grade data.

Broad incumbents

• Tempus Labs: U.S.-based precision medicine platform combining clinical, molecular, and imaging data to support treatment selection and clinical research. Operates at much larger scale but competes for the same multimodal data + clinical trial acceleration use case Okeiro addresses.
• Flatiron Health: Real-world evidence platform focused on oncology, aggregating EMR and clinical data for pharma-sponsored research. Comparable in the real-world evidence and clinical trial surrogate endpoint value proposition, though focused on oncology rather than transplantation.
• Komodo Health: Healthcare analytics platform providing real-world patient journey insights to life sciences companies. Comparable in the life-sciences-facing analytics and real-world evidence layer, though broader in therapeutic scope than Okeiro.
• Medidata Solutions (Dassault Systèmes): Clinical trial technology platform offering EDC, eCOA, and trial design tools to pharma sponsors. Most directly comparable in the clinical trial surrogate endpoint / TrialBox product layer, and the parent (Dassault Systèmes) is also headquartered in France.
• IQVIA: Global leader in clinical research services, real-world evidence, and healthcare data analytics. Competes for the same pharma RWE and clinical trial acceleration budgets Okeiro targets via TrialBox and the Digital Twin.

Emerging players

• Cardiologs: French AI platform for cardiac diagnostics (now part of Philips), illustrating another French health AI success in a single therapeutic area. Comparable on the French origin and clinical AI specialisation, but a different organ and use case (diagnostics vs. transplant care).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Okeiro